Chemomab Therapeutics (NASDAQ:CMMB) Releases Earnings Results

Chemomab Therapeutics (NASDAQ:CMMB) posted its earnings results on Wednesday. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.23), Zacks reports.

Chemomab Therapeutics Stock Performance

NASDAQ:CMMB opened at $2.09 on Thursday. The firm has a market cap of $15.05 million, a P/E ratio of -0.94 and a beta of 0.65. Chemomab Therapeutics has a 52 week low of $1.35 and a 52 week high of $4.12. The firm’s fifty day moving average is $1.72 and its 200-day moving average is $1.71.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Chemomab Therapeutics in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $25.00.

Hedge Funds Weigh In On Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. ADAR1 Capital Management LLC bought a new position in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $132,000. ADAR1 Capital Management LLC owned approximately 1.30% of Chemomab Therapeutics as of its most recent SEC filing. 46.05% of the stock is currently owned by institutional investors and hedge funds.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.